Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-06-10 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
东兴证券股份有限公司关于《中源协和细胞基因工程股份有限公司关于并购重组委会议审核意见的回复》之核查意见
M&A Activity Classification · 95% confidence The document is a detailed response from Dongxing Securities Co., Ltd. regarding the review comments from the M&A Committee of the China Securities Regulatory Commission (CSRC) on a merger and acquisition transaction involving Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. The text includes extensive disclosure about the company's development strategy, business integration plans, and internal control improvements following the acquisition. It also contains the independent financial advisor's verification opinion on these matters. The document references the M&A Committee's meeting results and the requirement to supplement disclosures related to the merger. The content is focused on merger-related disclosures and the company's strategic and operational plans post-merger, which aligns with filings related to merger and acquisition activities. It is not a full annual report, audit report, earnings release, or other financial report type. It is a formal response to regulatory review comments on an M&A transaction, which fits the category of M&A Activity (TAR). The document length (5113 characters) and detailed content confirm it is the actual response document, not just an announcement or certification. Therefore, the appropriate classification is M&A Activity (TAR).
2018-06-10 Chinese
关于发行股份购买资产并募集配套资金暨关联交易报告书（修订稿）修订说明的公告
Report Publication Announcement Classification · 95% confidence The document is an announcement regarding the revision and supplementary disclosure of a report related to issuance of shares to purchase assets and raise supporting funds, as well as related party transactions. It references a 'restructuring report' and mentions compliance with regulatory review by the China Securities Regulatory Commission. The document is short (570 characters) and primarily serves to notify about the revision and supplementary disclosure of the report, directing readers to the full report on the Shanghai Stock Exchange website. It does not contain the full report itself or detailed financial data, but rather an announcement about the report's revision and availability. Therefore, according to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2018-06-10 Chinese
发行股份购买资产并募集配套资金暨关联交易报告书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "重大资产重组报告书（修订稿）" which translates to "Major Asset Restructuring Report (Revised Draft)". It discusses the issuance of shares to purchase assets and the raising of supporting funds, including detailed transaction parties, pricing, share issuance, lock-up arrangements, profit forecasts, compensation arrangements, asset valuation, impact on company financials, approvals needed, risk disclosures, and commitments by directors and shareholders. The document references regulatory approvals by the China Securities Regulatory Commission (CSRC) and the Shanghai Stock Exchange, and includes extensive financial and transaction details. This is a comprehensive filing related to a significant asset acquisition and capital raising transaction, which fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result. Therefore, the appropriate classification is CAP with high confidence.
2018-06-10 Chinese
关于公司重大资产重组事项获得中国证监会上市公司并购重组审核委员会审核通过暨公司股票复牌的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (482 characters) regarding the approval of a major asset restructuring by the China Securities Regulatory Commission (CSRC) and the resumption of the company's stock trading. It mentions that the company has not yet received the formal approval document and will announce it later. There is no detailed financial data or full report included, only a regulatory update and stock resumption notice. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain the full asset restructuring report or financial statements. The document is not a full Annual Report, Capital/Financing Update, or Merger & Acquisition filing, but rather a regulatory announcement about the approval status and stock resumption.
2018-06-06 Chinese
关于注销已回购股权激励股份的公告
Transaction in Own Shares Classification · 95% confidence The document is a company announcement regarding the cancellation of repurchased restricted stock shares. It details the number of shares repurchased and cancelled, changes in share capital, and the updated share structure. The document is short (1010 characters) and focuses on share repurchase and cancellation activities, not on financial results or management discussion. It is not an annual or interim report, nor a regulatory certification or voting result. The content fits the category of Transaction in Own Shares, which covers company buybacks or share cancellations.
2018-06-06 Chinese
关于控股股东部分股权解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a controlling shareholder and the cumulative pledge status of shares. It contains specific details about share pledges and releases but does not include financial statements, management discussion, or other report content. The document is short (629 characters) and serves as a regulatory disclosure about share pledging activities. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-06-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.